Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to treat participants with the combination of durvalumab (the
study drug) and proton beam therapy. Proton beam therapy is a type of radiotherapy (RT) with
a unique characteristic where the proton stops at a specific depth according to its energy.
This may be advantageous in treating lung cancer because it allows for a sufficient tumor
dose that may improve local control and survival while sparing normal organs at risk, such as
the heart, lung, and spinal cord.